Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Maypharm Launches the world first Adipose Stem Cell Exosome hair filler, HAIRNA Exosome Hair Fill


News provided by

Maypharm

23 Aug, 2023, 09:00 GMT

Share this article

Share toX

Share this article

Share toX

SEOUL, South Korea and NEW YORK, Aug. 23, 2023 /PRNewswire/ -- Maypharm Launches the world first Adipose Stem Cell Exosome hair filler, HAIRNA Exosome Hair Fill. HAIRNA Exosome Hair Fill is developed with Maypharm's exclusive technology for scalp rejuvenation and hair growth.

Scalp Aging & Hair Loss

Continue Reading
This image opens in the lightbox
HAIRNA Exosome Hair Fill
This image opens in the lightbox
2XSOME

Alopecia and other hair anomalies can happen due to an array of causes, the most common being:

1.      Loss of collagen in hair follicles due to aging
2.      Loss of capillaries in the scalp, cutting oxygen and nutrient supply to the follicles
3.      Decrease in follicle size and increased oil production due to DHT hormone expression
4.      Reduced scalp regeneration and healing capacity due to compromised skin barrier
5.      Reduced pigment transport due to loss of melanocytes (grey hair)

Additional Active Ingredient

01  Biotinoyl Tripeptide-1

Biotin Tripeptide-1 is a three amino acid peptide that combines the famous collagen fragment, GHK with Biotin, a well-known supplement for stronger hair and nails. 

Biotinoyl Tripeptide-1 Benefits

1. Hair Cell Activation
Promotes keratinocyte proliferation at the follicle base and helps optimal hair anchorage by stimulating the synthesis of adhesion molecules - Laminin 5 and Collagen IV. 

2. Gene Expression Stimulation
Stimulates the expression of the Ki-67 gene, a proliferation marker protein associated with cellular proliferation as well as tissue recovery.

3. Hair Cell Metabolism Regulation
Promotes scalp microcirculation and stimulates cell communication, improving oxygen and nutrient supply to the hair follicles. 

02  Copper Tripeptide-1

Copper Tripeptide-1 (GHK-Cu) is a copper-peptide complex found naturally in bodily fluids such as plasma and saliva. With copper depletion being one of the causes for signs of skin aging and hair thinning, this tripeptide is quickly becoming a popular ingredient for hair and scalp treatments.

Copper Tripeptide-1 Benefits

1. Hair Follicle Enlargement
While studying GHK-Cu's wound healing properties, an enlargement of hair follicles around the area was found which eventually led to the discovery that copper peptides stimulate hair growth by stimulating follicular cell proliferation.

2. Hair Growth Cycle Regulation
Copper peptides stimulate and prolong the hair growth phase (Anagen), resulting in more time for active hair regrowth and thicker hair strands. They are also involved in shortening the inactive phase of the hair follicles (Telogen).

3. DHT Hormone Inhibition
Dihydrotestosterone (DHT), a hormone converted from testosterone, is the main cause of androgenetic hair loss. DHT is converted thanks to an enzyme known as 5-alpha reductase, which peptides have been shown to obstruct.

03  Polypeptide

1. sh-Polypeptide-1 (FGF2)
Synthesized copy of the human gene coding for Basic Fibroblast Growth Factor (FGF2). Stimulates fibroblast and keratinocyte cell growth and proliferation, as well as the synthesis of collagen and other  extracellular matrix components, promoting skin barrier health.

2. sh-Polypeptide-4 (SCF)
Synthesized copy of the human gene coding for Stem Cell Factor (SCF). Plays an important role in the formation of blood cells and melanocytes, regulating the survival and proliferation of melanocytes in adults to maintain a normal pigment transport (grey hair prevention).

3. sh-Polypeptide-12 (NOG)
Synthesized copy of the human gene coding for Noggin protein (NOG). Noggin is a signaling molecule that plays a role in tissue development and the derivation of specialized cells.Studies show that Noggin signaling is required for induction of the hair follicle growth phase (Anagen).

HAIRNA Exosome Hair Fill & The Hair Growth Cycle

Biotin Tripeptide-1 is a three amino acid peptide that combines the famous collagen fragment, GHK with Biotin, a well-known supplement for stronger hair and nails. The resulting Biotinoyl Tripeptide-1 has shown hair regrowth effects comparable to those of Minoxidil.

In addition to HAIRNA Exosome Hair Fill, Maypharm has launched such popular human stem cell products such as 2XSOME for face and neck.

Backed by extensive clinical research, Maypharm products have been thoroughly tested and embraced by countless individuals to worldwide acclaim.

Whether you are looking to improve your appearance or to regain self-confidence, HAIRNA Exosome Hair Fill is a solution that is hard to beat.

For further details, please contact us at maypharm@maypharm.co.kr, or visit our website at https://www.may-pharm.com/

Photo - https://mma.prnewswire.com/media/2189970/image_1.jpg

Photo - https://mma.prnewswire.com/media/2189971/image_2.jpg

Modal title

Also from this source

MAYPHARM CO., LTD. Launches SKINCOLLA: The World's First Recombinant Human Collagen Filler for Superior Skin Rejuvenation

MAYPHARM CO., LTD. Launches SKINCOLLA: The World's First Recombinant Human Collagen Filler for Superior Skin Rejuvenation

MAYPHARM CO., LTD. proudly introduces SKINCOLLA, the world's first recombinant human collagen filler, marking a significant breakthrough in skin...

Maypharm Unveils Revolutionary Hybrid Filler, Hyalmass Aqua-Exosome: The Future of Skin Hydration and Regeneration

Maypharm Unveils Revolutionary Hybrid Filler, Hyalmass Aqua-Exosome: The Future of Skin Hydration and Regeneration

Maypharm Co., Ltd., a leading innovator in medical and dermo-cosmetic products, proudly introduces the global launch of Hyalmass Aqua-Exosome, a...

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Household, Consumer & Cosmetics

Household, Consumer & Cosmetics

Medical Pharmaceuticals

Medical Pharmaceuticals

Pharmaceuticals

Pharmaceuticals

News Releases in Similar Topics

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.